Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence

References

• Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386:1097–1108. doi:10.1016/S0140-6736(15)60733-4
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–427. doi:10.1056/NEJMoa1500245
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155–163. doi:10.1056/NEJMoa1209165
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, et al. Adults Hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65:1806–1812. doi:10.1093/cid/cix647
   PubMed Web of Science ®Google Scholar
• Bordon J, Slomka M, Gupta R, et al. Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes. Clin Microbiol Infect. 2020;26:220–226. doi:10.1016/j.cmi.2019.06.025
   Web of Science ®Google Scholar
• File TM. Community-acquired pneumonia. Lancet. 2003;362:1991–2001. doi:10.1016/S0140-6736(03)15021-0
   PubMed Web of Science ®Google Scholar
• Lim WS, Macfarlane JT, Boswell TCJ, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56:296–301. doi:10.1136/thorax.56.4.296
   PubMed Web of Science ®Google Scholar
• Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50:202–209. doi:10.1086/648678
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200:E45–E67. doi:10.1164/rccm.201908-1581ST
   PubMed Web of Science ®Google Scholar
• Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: A systematic review and meta-analysis. Eur Respir Rev. 2016;25:178–188. doi:10.1183/16000617.0076-2015
   PubMed Web of Science ®Google Scholar
• Holter JC, Müller F, Bjørang O, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: A 3-year prospective study in Norway. BMC Infect Dis. 2015;15:64. doi:10.1186/s12879-015-0803-5
   PubMed Web of Science ®Google Scholar
• Gadsby NJ, Russell CD, Mchugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62:817–823. doi:10.1093/cid/civ1214
   PubMed Web of Science ®Google Scholar
• Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12:153–160. doi:10.1513/AnnalsATS.201407-305OC
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:1–13. doi:10.1136/bmj.j2471
   Web of Science ®Google Scholar
• Lim WS, Baudouin S, George R, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–55. doi:10.1136/thx.2009.121434
   PubMed Web of Science ®Google Scholar
• Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42:420–432. doi:10.1097/CCM.0b013e3182a66b9b
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33:153–159. doi:10.1183/09031936.00054108
   PubMed Web of Science ®Google Scholar
• Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia a systematic review. JAMA - J Am Med Assoc. 2016;315:593–602. doi:10.1001/jama.2016.0115
   PubMed Web of Science ®Google Scholar
• Postma DF, Van Werkhoven CH, Van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–1323. doi:10.1056/NEJMoa1406330
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416. doi:10.1164/rccm.200405-644ST
   PubMed Web of Science ®Google Scholar
• Grenier C, Pépin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother. 2011;66:1617–1624. doi:10.1093/jac/dkr176
   PubMed Web of Science ®Google Scholar
• Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci. 2007;333:161–167. doi:10.1097/MAJ.0b013e3180312cd5
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-Analysis. Clin Infect Dis. 2006;42:788–797. doi:10.1086/500140
   PubMed Web of Science ®Google Scholar
• Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48:1596–1600. doi:10.1086/598975
   PubMed Web of Science ®Google Scholar
• Cherazard R, Epstein M, Doan TL, et al. Antimicrobial resistant Streptococcus pneumoniae. Am J Ther. 2017;24:e361–e369. doi:10.1097/MJT.0000000000000551
   PubMed Web of Science ®Google Scholar
• Schroeder MR, Stephens DS. Macrolide resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol. 2016;6:1–9. doi:10.3389/fcimb.2016.00098
   Web of Science ®Google Scholar
• Haran JP, Volturo GA. Macrolide resistance in cases of community-acquired bacterial pneumonia in the Emergency Department. J Emerg Med. 2018;55:347–353. doi:10.1016/j.jemermed.2018.04.031
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–S72. doi:10.1086/511159
   PubMed Web of Science ®Google Scholar
• Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis. 2016;63:300–309. doi:10.1093/cid/ciw300
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. FDA. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics. Accessed Jul 6, 2020.
   Google Scholar
• Mogle BT, Steele JM, Thomas SJ, et al. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73:1439–1451. doi:10.1093/jac/dkx543
   PubMed Web of Science ®Google Scholar
• Horcajada JP, Salata RA, Álvarez-Sala R, et al. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (Define-CABP). Open Forum Infect Dis. 2020;7:1–13. doi:10.1093/ofid/ofz514
   Web of Science ®Google Scholar
• Melinta Therapeutics announces U.S. FDA approval of supplemental new drug application for BAXDELA® (delafloxacin) for the treatment of community-acquired bacterial pneumonia (CABP). Melinta Therapeutics, Inc. Available from: http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new. Accessed Jul 6, 2020.
   Google Scholar
• Baker DE. Omadacycline. Hosp Pharm. 2019;54:80–87. doi:10.1177/0018578718823730
   PubMed Web of Science ®Google Scholar
• Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527. doi:10.1056/NEJMoa1800201
   PubMed Web of Science ®Google Scholar
• Chambers HF. Omadacycline - The newest tetracycline. N Engl J Med. 2019;380:588–589. doi:10.1056/NEJMe1900188
   PubMed Web of Science ®Google Scholar
• Falcó V, Burgos J, Almirante B. An overview of lefamulin for the treatment of community acquired bacterial pneumonia. Expert Opin Pharmacother. 2020;21:629–636. doi:10.1080/14656566.2020.1714592
   PubMed Web of Science ®Google Scholar
• File TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the Phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69:1856–1867. doi:10.1093/cid/ciz090
   PubMed Web of Science ®Google Scholar
• Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA - J Am Med Assoc. 2019;322:1661–1671. doi:10.1001/jama.2019.15468
   PubMed Web of Science ®Google Scholar
• Sakoulas GM. U.S. FDA approves lefamulin for community-acquired bacterial pneumonia. NEJM J Watch. 2019. doi:10.1056/NEJM-JW.NA49805
   Google Scholar
• Donald BJ, Surani S, Deol HS, et al. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;1:3559–3566. doi:10.2147/DDDT.S119545
   Web of Science ®Google Scholar
• Barrera CM, Mykietiuk A, Metev H, et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016;16:421–430. doi:10.1016/S1473-3099(16)00017-7
   PubMed Web of Science ®Google Scholar
• File TM, Rewerska B, Vucinić-Mihailović V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016;63:1007–1016. doi:10.1093/cid/ciw490
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document. Solithromycin oral capsule and injection meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). November. 2016;4.
   Google Scholar
• Lai CC, Liu WL, Ko WC, et al. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species. Antimicrob Agents Chemother. 2011;55:2084–2091. doi:10.1128/AAC.01808-10
   PubMed Web of Science ®Google Scholar
• Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58:1800–1801. doi:10.1128/AAC.02263-13
   PubMed Web of Science ®Google Scholar
• Chang SP, Lee HZ, Lai CC, Tang HJ. The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:433–438. doi:10.2147/IDR.S193233
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Wu J, et al. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. J Microbiol Immunol Infect. 2017;50:811–820. doi:10.1016/j.jmii.2015.09.005
   PubMedGoogle Scholar
• Amalakuhan B, Echevarria KL, Restrepo MI. Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon. Expert Opin Pharmacother. 2017;18:1039–1048. doi:10.1080/14656566.2017.1340937.MANAGING
   PubMed Web of Science ®Google Scholar
• Yuan J, Mo B, Ma Z, et al. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect. 2019;52:35–44. doi:10.1016/j.jmii.2017.07.011
   PubMedGoogle Scholar
• Van Rensburg DJJ, Perng RP, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54:4098–4106. doi:10.1128/AAC.00295-10
   PubMed Web of Science ®Google Scholar
• Kwon AR, Min YH, Ryu JM, et al. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother. 2006;58:684–688. doi:10.1093/jac/dkl304
   PubMed Web of Science ®Google Scholar
• Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15:1–8. doi:10.1186/s12941-016-0150-4
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of oral zabofloxacin in community-acquired pneumonia. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01081964?cond=zabofloxacin&draw=2&rank=2. Accessed Jul 17, 2020.
   Google Scholar
• Morrow BJ, He W, Amsler KM, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 2010;54:1955–1964. doi:10.1128/AAC.01374-09
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Farrell DJ, Flamm RK, et al. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2012;39:321–325. doi:10.1016/j.ijantimicag.2011.11.016
   PubMed Web of Science ®Google Scholar
• Covington PS, Davenport JM, Andrae DA, et al. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia. J Antimicrob Chemother. 2013;68:2691–2693. doi:10.1093/jac/dkt217
   PubMed Web of Science ®Google Scholar
• Krokidis MG, Márquez V, Wilson DN, et al. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. Antimicrob Agents Chemother. 2014;58:472–480. doi:10.1128/AAC.01994-13
   PubMed Web of Science ®Google Scholar
• Flamm RK, Rhomberg PR, Sader HS. In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. Antimicrob Agents Chemother. 2017;61:1–8. doi:10.1128/AAC.01230-17
   Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Chugh R, et al. Comparison of plasma and intrapulmonary concentrations of nafithromycin (WCK 4873) in healthy adult subjects. Antimicrob Agents Chemother. 2017;61:1–9. doi:10.1128/AAC.01096-17
   Web of Science ®Google Scholar
• Phase II study of oral nafithromycin in CABP - Study results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02903836. Accessed Jul 7, 2020.
   Google Scholar
• Grossman TH, Fyfe C, O’Brien W, et al. Fluorocycline TP-271 is potent against complicated community-acquired bacterial pneumonia pathogens. mSphere. 2017;2(1):e00004–17. doi:10.1128/mSphere.00004-17
   Web of Science ®Google Scholar
• A Phase 1 study to assess the safety, tolerability and PK of IV TP-271. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02724085. Accessed Jul 7, 2020.
   Google Scholar
• Tiffany CA, Hossain M, McDonald M, et al. Safety and pharmacokinetics of single escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor. Abstr 53rd Intersci Conf Antimicrob Agents Chemother. 2013;abstr F–1218.
   Google Scholar
• Lemaire S, Kosowska-Shick K, Appelbaum PC, et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010;54:2549–2559. doi:10.1128/AAC.01724-09
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of oxazolidinone to treat pneumonia. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00640926?cond=radezolid&draw=2&rank=1. Accessed Jul 7, 2020.
   Google Scholar
• Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013;26:792–821. doi:10.1128/CMR.00033-13
   PubMed Web of Science ®Google Scholar
• Multiple ascending dose study for LCB01–0371. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01842516. Accessed Jul 7, 2020.
   Google Scholar
• Henry BD, Neill DR, Becker KA, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33:81–88. doi:10.1038/nbt.3037
   PubMed Web of Science ®Google Scholar
• Laterre PF, Colin G, Dequin PF, et al. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2019;19:620–630. doi:10.1016/S1473-3099(18)30805-3
   PubMed Web of Science ®Google Scholar